JP2019527563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527563A5 JP2019527563A5 JP2019526196A JP2019526196A JP2019527563A5 JP 2019527563 A5 JP2019527563 A5 JP 2019527563A5 JP 2019526196 A JP2019526196 A JP 2019526196A JP 2019526196 A JP2019526196 A JP 2019526196A JP 2019527563 A5 JP2019527563 A5 JP 2019527563A5
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- gene construct
- modified gene
- mir
- target cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002679 microRNA Substances 0.000 claims description 67
- 108700011259 MicroRNAs Proteins 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108091033433 MiR-191 Proteins 0.000 claims description 2
- 108091028695 MiR-224 Proteins 0.000 claims description 2
- 108091062154 Mir-205 Proteins 0.000 claims description 2
- 108091027559 Mir-96 microRNA Proteins 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 108091059964 miR-154 stem-loop Proteins 0.000 claims description 2
- 108091029500 miR-183 stem-loop Proteins 0.000 claims description 2
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 2
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 2
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims description 2
- 108091092564 miR-494 stem-loop Proteins 0.000 claims description 2
- 108091063340 miR-497 stem-loop Proteins 0.000 claims description 2
- -1 miR-720 Proteins 0.000 claims description 2
- 108091086713 miR-96 stem-loop Proteins 0.000 claims description 2
- 108091070961 miR-96-3 stem-loop Proteins 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366755P | 2016-07-26 | 2016-07-26 | |
| US62/366,755 | 2016-07-26 | ||
| PCT/US2017/043938 WO2018022749A1 (en) | 2016-07-26 | 2017-07-26 | Spatiotemporal regulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527563A JP2019527563A (ja) | 2019-10-03 |
| JP2019527563A5 true JP2019527563A5 (cg-RX-API-DMAC7.html) | 2020-09-03 |
Family
ID=59523304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526196A Pending JP2019527563A (ja) | 2016-07-26 | 2017-07-26 | 時空間調節因子 |
| JP2019526195A Pending JP2019521717A (ja) | 2016-07-26 | 2017-07-26 | 遺伝子イレーサー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526195A Pending JP2019521717A (ja) | 2016-07-26 | 2017-07-26 | 遺伝子イレーサー |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190233844A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3491137A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2019527563A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190053179A (cg-RX-API-DMAC7.html) |
| CN (2) | CN110073000A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017302587A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3031673A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018022747A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| US20210228627A1 (en) * | 2018-05-15 | 2021-07-29 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3120093A1 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for compartment-specific cargo delivery |
| JP7558272B2 (ja) * | 2019-11-19 | 2024-09-30 | プロタリクス リミテッド | 形質転換細胞からの構築物の除去 |
| GB202006462D0 (en) * | 2020-05-04 | 2020-06-17 | Mote Res Limited | Modifying genomes with integrase |
| JP2024532963A (ja) | 2021-04-08 | 2024-09-11 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８特異的抗体コンストラクト及びその組成物 |
| WO2025006468A2 (en) | 2023-06-26 | 2025-01-02 | University Of Hawaii | Evolved integrases and methods of using the same for genome editing |
| CN118813656B (zh) * | 2024-06-19 | 2025-06-03 | 山东大学 | 一种大片段dna级联组装的方法、系统及应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834430C2 (de) * | 1998-07-30 | 2000-05-31 | Harald Von Melchner | Selbstdeletierende Vektoren für die Krebstherapie |
| US7189506B1 (en) * | 1999-03-03 | 2007-03-13 | Genelabs Technologies, Inc. | DNA binding compound-mediated molecular switch system |
| US20060265771A1 (en) * | 2005-05-17 | 2006-11-23 | Lewis David L | Monitoring microrna expression and function |
| SI2002003T1 (sl) * | 2005-05-27 | 2016-05-31 | Ospedale San Raffaele S.R.L. | Genski vektor, ki vsebuje mi-RNA |
| CA2610702A1 (en) * | 2005-06-03 | 2006-12-07 | Michael Zenon Michael | Targeting cells with altered microrna expression |
| US20070054872A1 (en) * | 2005-08-24 | 2007-03-08 | Mirus Bio Corporation | Regulatable or conditional expression systems |
| EP2069778A2 (en) * | 2006-08-03 | 2009-06-17 | Numira Biosciences, Inc. | Methods and compositions for identifying biomarkers |
| US20090286242A1 (en) * | 2007-12-10 | 2009-11-19 | Cold Spring Harbor Laboratory | MicroRNA Expression Profiling and Uses Thereof |
| US20110098346A1 (en) * | 2008-05-19 | 2011-04-28 | Agency For Science, Technology And Research | Nucleic acid molecule and method of targeting gene expression to gliomas |
| US20100229254A1 (en) * | 2009-03-04 | 2010-09-09 | Kmita Marie | Method for targeted cell ablation |
| JP2013533847A (ja) * | 2010-04-23 | 2013-08-29 | ユニバーシティ オブ マサチューセッツ | コレステロール関連障害のａａｖベースの治療 |
| WO2012056440A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA |
| CN102719556A (zh) * | 2011-03-29 | 2012-10-10 | 北京五加和分子医学研究所有限公司 | 基于AAV载体的高通量miRNA活性检测方法及其应用 |
| EP2691525A1 (en) * | 2011-03-31 | 2014-02-05 | Royal College of Surgeons in Ireland | Treatment and prognosis of solid tumour cancers |
| CN102358901A (zh) * | 2011-11-11 | 2012-02-22 | 天津托普泰克生物科技有限公司 | Has-miR-520e的抗肿瘤用途 |
| EP2684962A1 (en) * | 2012-07-10 | 2014-01-15 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Vector for the selective silencing of a gene in astrocytes |
| JP6419082B2 (ja) * | 2012-12-13 | 2018-11-07 | マサチューセッツ インスティテュート オブ テクノロジー | リコンビナーゼに基づく論理／メモリシステム |
| WO2014115158A1 (en) * | 2013-01-28 | 2014-07-31 | Council Of Scientific & Industrial Research | METHOD FOR INHIBITING TUMOR GROWTH THROUGH RNA-INTERFERENCE USING LIPOSOMALLY ASSOCIATED CDC20 siRNA |
| FR3004463A1 (fr) * | 2013-04-11 | 2014-10-17 | Genethon | Systeme d'expression pour une therapie genique selective |
| EP3209311B1 (en) * | 2014-10-21 | 2024-03-06 | University of Massachusetts | Recombinant aav variants and uses thereof |
| JP2016088884A (ja) * | 2014-11-04 | 2016-05-23 | 国立大学法人岐阜大学 | 腫瘍治療用組成物 |
| CN108350445A (zh) | 2015-06-19 | 2018-07-31 | 麻省理工学院 | 肿瘤免疫治疗 |
| US11174495B2 (en) * | 2015-12-04 | 2021-11-16 | Board Of Regents, The University Of Texas System | Reporter system for detecting and targeting activated cells |
-
2017
- 2017-07-26 AU AU2017302587A patent/AU2017302587A1/en not_active Abandoned
- 2017-07-26 US US16/319,791 patent/US20190233844A1/en not_active Abandoned
- 2017-07-26 CN CN201780057742.XA patent/CN110073000A/zh active Pending
- 2017-07-26 CA CA3031673A patent/CA3031673A1/en not_active Abandoned
- 2017-07-26 KR KR1020197005575A patent/KR20190053179A/ko not_active Withdrawn
- 2017-07-26 EP EP17749048.9A patent/EP3491137A1/en not_active Withdrawn
- 2017-07-26 CN CN201780058989.3A patent/CN110088285A/zh active Pending
- 2017-07-26 WO PCT/US2017/043931 patent/WO2018022747A1/en not_active Ceased
- 2017-07-26 CA CA3031670A patent/CA3031670A1/en active Pending
- 2017-07-26 WO PCT/US2017/043938 patent/WO2018022749A1/en not_active Ceased
- 2017-07-26 JP JP2019526196A patent/JP2019527563A/ja active Pending
- 2017-07-26 US US16/319,786 patent/US20190169634A1/en not_active Abandoned
- 2017-07-26 AU AU2017302589A patent/AU2017302589A1/en not_active Abandoned
- 2017-07-26 EP EP17754865.8A patent/EP3491138A1/en not_active Withdrawn
- 2017-07-26 KR KR1020197005579A patent/KR20190053180A/ko not_active Ceased
- 2017-07-26 JP JP2019526195A patent/JP2019521717A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527563A5 (cg-RX-API-DMAC7.html) | ||
| Diener et al. | Emerging concepts of miRNA therapeutics: from cells to clinic | |
| Simonson et al. | MicroRNA therapeutics: the next magic bullet? | |
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| CN106540268B (zh) | 一种TDNs-AS1411-核酸药物复合纳米材料载药系统及其制备方法 | |
| Giza et al. | Key principles of miRNA involvement in human diseases | |
| JP2017509350A5 (cg-RX-API-DMAC7.html) | ||
| Xue et al. | MicroRNA-targeted therapeutics for lung cancer treatment | |
| JP2009519339A5 (cg-RX-API-DMAC7.html) | ||
| Aránega et al. | MiRNAs and muscle regeneration: therapeutic targets in Duchenne muscular dystrophy | |
| JP2015513919A5 (cg-RX-API-DMAC7.html) | ||
| JP2014518875A5 (cg-RX-API-DMAC7.html) | ||
| JP2022536951A (ja) | 環状ポリリボヌクレオチドを投与する方法 | |
| CN105899663B (zh) | 用于基因表达控制的人工模拟miRNA及其用途 | |
| Pfeifer et al. | Harnessing synthetic biology for advancing RNA therapeutics and vaccine design | |
| Dai et al. | Pancreatic cancer: Nucleic acid drug discovery and targeted therapy | |
| Zhao et al. | microRNAs: critical targets for treating rheumatoid arthritis angiogenesis | |
| Cao et al. | Engineering circular RNA medicines | |
| Dong et al. | Non‐coding RNAs in cardiomyocyte proliferation and cardiac regeneration: dissecting their therapeutic values | |
| Najmuddin et al. | The linkage between microRNA and cancer and its delivery as cancer therapy: a mini-review | |
| kuji Kosuge et al. | Identification 0f 0bstructive Jaundice-Related MicroRNAS in Mouse Liver | |
| JP2025049296A (ja) | 高度にコンパクトな多入力論理ゲートをコードする核酸ベクターを使用して疾患を処置する方法 | |
| Zhang et al. | Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy | |
| Tömböl et al. | Relevance of microRNA-s in neoplastic diseases | |
| Leonard et al. | Small non-coding RNAs and aptamers in diagnostics and therapeutics |